Novo Nordisk’s Sickle Cell Drug Delivers as Buyback Program Advances
Novo Nordisk’s oral sickle cell drug etavopivat met Phase 3 goals, cutting painful crises by 27%. The success…
European Lithium’s Valuation Gap Narrows as Greenland Project Advances
European Lithium’s 12% surge follows Greenland project approval, revealing a valuation gap where its cash and Critical Metals…
Novo Nordisk Advances Share Buyback Amid Market Pressures
Danish pharmaceutical giant Novo Nordisk is proceeding with its multi-billion kroner share repurchase initiative, a move that underscores…